---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic impact of diagnostic testing"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Economic impact of diagnostic testing. Topics: Medicare payment for NPC1 and NPC2 gene sequencing, 2026; Medicare payment for exome and genome sequencing, 2026; Cost-effectiveness of plasma oxysterol screening in intellectually disabled patients in Canada; Gene panel cost and test selection in the Australian standard of care; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/economic-impact-of-diagnostic-testing"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic impact of diagnostic testing

<a id="heading-2.2.1.8.4"></a>

## 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

### Medicare payment for NPC1 and NPC2 gene sequencing, 2026

> “2026,81406,,20260101,N,00282.88,Mopath procedure level 7”
> “npc1 (niemann-pick disease, type c1) (eg, niemann-pick disease), full gene sequence”
> “2026,81404,,20260101,N,00274.83,Mopath procedure level 5”
> “npc2 (niemann-pick disease, type c2 [epididymal secretory protein e1]) (eg, niemann-pick disease type c2), full gene sequence”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

<a id="topic-2.2.1.8.4-2"></a>

### Medicare payment for exome and genome sequencing, 2026

> “2026,81415,,20260101,N,04780.00,Exome sequence analysis”
> “Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis”
> “2026,81425,,20260101,N,05031.20,Genome sequence analysis”
> “Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis”

Source: [CMS Clinical Laboratory Fee Schedule (2026)](https://www.cms.gov/files/zip/26clabq4.zip)

<a id="topic-2.2.1.8.4-3"></a>

### Cost-effectiveness of plasma oxysterol screening in intellectually disabled patients in Canada

> “Our objective is to compare costs and outcomes of plasma oxysterol screening versus current practice in diagnosis of NP-C disease among intellectually disabled (ID) patients using decision-analytic methods.”
> “The outcomes of the base case model showed that using plasma oxysterol screening for diagnosis of NP-C disease among ID patients is a dominant strategy.”
> “The average amount of cost saving was $3642 CAD and the incremental QALYs per each individual ID patient in oxysterol screening arm versus current practice of diagnosis NP-C was 0.0022 QALYs.”

Source: [van Karnebeek et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25095726/)

<a id="topic-2.2.1.8.4-4"></a>

### Gene panel cost and test selection in the Australian standard of care

> “Multigene panels are becoming more accessible and cost‐effective.”
> “When gene panel tests are used, they should be symptom‐specific and must include the NPC1 and NPC2 genes.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.1.8.4-5"></a>

### Manufacturer-sponsored exome testing at no charge in the United States

> “Through the program, GeneDx is slated to offer testing to U.S.-based clinicians caring for patients with known or suspected NPC who meet eligibility criteria.”
> “Patients will then be eligible to receive GeneDx's ExomeDx test at no charge and results will be provided to clinicians and their patients in as little as three weeks.”
> “Zevra Therapeutics will provide financial support for the program as part of its commitment to advancing diagnosis and care in NPC.”

Source: [GeneDx Zevra NPC sponsored genetic testing program press release (2026)](https://www.businesswire.com/news/home/20260310450068/en)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
